Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time, the ...

Caribou is enrolling a 20-patient confirmatory cohort using the company's HLA matching strategy in the ANTLER Phase 1 clinical trial in second-line large B cell lymphoma (2L LBCL). In H2 2025, Caribou ...

Caribou Biosciences (CRBU) announced a strategic pipeline prioritization with workforce and cost reduction initiatives to focus resources on ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...